PUBLIC COMPANY
save$SNYNFSanofi
$SNYNFupdated 3mo ago
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval433 co-mentions · 217 sources
- company$SNYSanofi234 co-mentions · 225 sources
- drugRIFADIN233 co-mentions · 117 sources
- tagSmall Molecule168 co-mentions · 168 sources
- drugrifampin117 co-mentions · 117 sources
- drugRIFATER50 co-mentions · 25 sources
- drugPRIMAQUINE36 co-mentions · 18 sources
- drugPRIFTIN34 co-mentions · 17 sources
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Sanofi’s immunology reckoning; Lilly acquires in vivo CAR-T biotech; RevMed’s ‘Herceptin moment’; and moreWelcome back to another edition of Endpoints Weekly! We’re doing a little bit of celebrating here at Endpoints, as we took home three Neal Awards, which recognize excellence in B2B journalism. The ...endpoints · 3mo ago
- STAT+: FDA to speed up review of three psychedelics as mental health treatmentsTrump's embrace of psychedelics and cannabis is shaking up the GOP’s relationship with mind-altering substances.stat · 3mo ago
- Sanofi MS drug rejected in US gets an endorsement in EuropeTolebrutinib, which the FDA recently turned back due to safety concerns, received a positive recommendation that positions the therapy for its first regulatory approval.biopharma_dive · 3mo ago
- STAT+: Sanofi MS drug gets positive review in Europe following FDAA multiple sclerosis drug from Sanofi that was rejected late last year by the FDA found a warmer reception in Europe.stat · 3mo ago
- Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejectionSanofi’s tolebrutinib is on track to get an approval in Europe for a type of multiple sclerosis even after receiving a complete response letter from the FDA in December. On Friday, the European Med…endpoints · 3mo ago
- STAT+: Trump celebrates closing first round of drug pricing deals, promises more aheadA deal with Regeneron was the last of 17 initially sought by the White House.stat · 3mo ago
- STAT+: Sanofi research priorities in flux as new CEO logs inA gene therapy for deafness, all eyes on Erasca, and other biotech news from The Readoutstat · 3mo ago
- Sanofi posts upbeat sales as R&D pressure buildsA string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over. But positive first-quarter earnings provided the company with a needed boost.biopharma_dive · 3mo ago
- Sanofi defends Garijo appointment, says it is 'fully committed' to immunologySanofi’s first-quarter earnings call with the media on Thursday was an exercise in redirecting the narrative before its new CEO steps in next week. CFO François-Xavier Roger defended the company’s…endpoints · 3mo ago
- Merck adds to pharma’s AI push; Roche details MS drug resultsMerck is making a $1 billion investment in a deal with Google Cloud. Elsewhere, Roche pitched its case for a closely watched multiple sclerosis pill and Arcus and Gilead are ending a yearslong alli…biopharma_dive · 3mo ago
Data sources
last refreshed 32m ago
Found something off?
comments(0)
5-min edit window · permanent after that